At AACE 2017, John Bilezikian, MD, Professor of Medicine and Pharmacology at the College of Physicians & Surgeons, Columbia University, Chief, Emeritus, of the of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center discussed the latest FDA approval of Tymlos for postmenopausal women with osteoporosis and for women who are at high risk for fracture.

“The development of this drug was very beautifully designed, and it turns out as the clinical trials were developed, that this drug proved itself, that it did do what we thought it would do.” Tymlos was found to markedly increase bone density in a very significant way and reduce fractures in postmenopausal women both at and outside the vertebral column.



Leave a reply

©2024 SHIVAWATER™ by General Intelligent Services and Productions, LLC., authorized by Bassocco, Est. 1992, first brand in the world to bottle and distribute alkaline water, all rights reserved. If you use our website in any form, it means you have accepted our Terms and Conditions. Questions? Contact us.

©2024 SHIVAWATER™ de General Intelligent Services and Productions, LLC., autorizada por Bassocco, Est. 1992, la primera marca en el mundo en embotellar y distribuir agua alcalina, todos los derechos reservados. Si utiliza nuestro sitio web en cualquier forma, significa que ha aceptado nuestros Términos y condiciones. ¿Preguntas? Contáctanos.


We're not around right now. But you can send us an email so we'll get back to you.


Log in with your credentials

Forgot your details?